STOCK TITAN
  1. Home
  2. News
  3. GMDA

Gamida Cell Ltd - GMDA STOCK NEWS

IMPACT
SENTIMENT
GMDA : Nasdaq
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
clinical trial
IMPACT
SENTIMENT
GMDA : Nasdaq
Gamida Cell Issues Update on Israel Operations
IMPACT
SENTIMENT
GMDA : Nasdaq
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
conferences
IMPACT
SENTIMENT
GMDA : Nasdaq
Gamida Cell to Present at Society for Immunotherapy of Cancer';s (SITC) 38th Annual Meeting
conferences
IMPACT
SENTIMENT
GMDA : Nasdaq
First Patient Receives Gamida Cell';s Omisirge™ (omidubicel-onlv)
IMPACT
SENTIMENT
GMDA : Nasdaq
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference
conferences
IMPACT
SENTIMENT
GMDA : Nasdaq ADES : Nasdaq
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
earnings
IMPACT
SENTIMENT
GMDA : Nasdaq
Gamida Cell to Report Second Quarter 2023 Financial Results
conferences earnings
IMPACT
SENTIMENT
GMDA : Nasdaq
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)
IMPACT
SENTIMENT
GMDA : Nasdaq
STAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE OFFICER
Stock GMDA logo
Gamida Cell Ltd
Nasdaq:GMDA

GMDA Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link

About GMDA

gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.